An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder

Bibliography

• Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009;374(9688):491-9
   PubMed Web of Science ®Google Scholar
• Ferrao YA, Shavitt RG, Prado H, et al. Sensory phenomena associated with repetitive behaviors in obsessive-compulsive disorder: an exploratory study of 1001 patients. Psychiatry Res 2012;197(3):253-8
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010;15(1):53-63
   PubMed Web of Science ®Google Scholar
• Fontenelle IS, Fontenelle LF, Borges MC, et al. Quality of life and symptom dimensions of patients with obsessive-compulsive disorder. Psychiatry Res 2010;179(2):198-203
   PubMed Web of Science ®Google Scholar
• Fernandez Cordoba E, Lopez-Ibor Alino J. [Use of monochlorimipramine in psychiatric patients who are resistant to other therapy]. Actas Luso Esp Neurol Psiquiatr 1967;26(2):119-47
   PubMedGoogle Scholar
• Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991;48(8):730-8
   Google Scholar
• Fineberg NA, Reghunandanan S, Brown A, et al. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust NZ J Psychiatry 2013;47(2):121-41
   PubMed Web of Science ®Google Scholar
• Fontenelle LF, Barbosa IG, Luna JV, et al. Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res 2012;199(3):195-200
   PubMed Web of Science ®Google Scholar
• Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44(11):946-51
   PubMedGoogle Scholar
• Pigott TA, Zohar J, Hill JL, et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 1991;29(5):418-26
   PubMed Web of Science ®Google Scholar
• Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992;49(1):21-8
   PubMed Web of Science ®Google Scholar
• Khanna S, John JP, Reddy LP. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder. Psychoneuroendocrinology 2001;26(2):209-23
   PubMed Web of Science ®Google Scholar
• Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 2001;11(2):169-72
   PubMed Web of Science ®Google Scholar
• Gross-Isseroff R, Cohen R, Sasson Y, et al. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 2004;50(3):200-5
   PubMed Web of Science ®Google Scholar
• Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20(11):1174-88
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Kruesi MJ, et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49(1):29-36
   PubMed Web of Science ®Google Scholar
• Pogarell O, Hamann C, Popperl G, et al. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 2003;54(12):1406-13
   PubMed Web of Science ®Google Scholar
• Stengler-Wenzke K, Muller U, Angermeyer MC, et al. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci 2004;254(4):252-5
   PubMed Web of Science ®Google Scholar
• Hesse S, Muller U, Lincke T, et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res 2005;140(1):63-72
   PubMed Web of Science ®Google Scholar
• Reimold M, Smolka MN, Zimmer A, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. J Neural Transm 2007;114(12):1603-9
   PubMed Web of Science ®Google Scholar
• Zitterl W, Aigner M, Stompe T, et al. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 2007;32(8):1661-8
   PubMed Web of Science ®Google Scholar
• Berney A, Leyton M, Gravel P, et al. Brain regional {alpha}-[11C]methyl-L-tryptophan trapping in medication-free patients with obsessive-compulsive disorder. Arch Gen Psychiatry 2011;68(7):732-41
   PubMedGoogle Scholar
• Bloch MH, Landeros-Weisenberger A, Sen S, et al. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet 2008;147B(6):850-8
   PubMed Web of Science ®Google Scholar
• Fontenelle L, Nardi AE, Marques C, et al. [Inibidores seletivos de recaptação de serotonina no transtorno obsessivo-compulsivo]. J Bras Psiq 1997;46(9):487-98
   Google Scholar
• Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60(2):101-6
   PubMed Web of Science ®Google Scholar
• Vythilingum B, Cartwright C, Hollander E. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2000;15(Suppl 2):S7-13
   PubMedGoogle Scholar
• Jenike MA, Baer L, Summergrad P, et al. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989;146(10):1328-30
   PubMed Web of Science ®Google Scholar
• Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990;28(5):401-14
   PubMed Web of Science ®Google Scholar
• Greist JH, Jefferson JW, Rosenfeld R, et al. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J Clin Psychiatry 1990;51(7):292-7
   PubMed Web of Science ®Google Scholar
• Mavissakalian MR, Jones B, Olson S, et al. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol 1990;10(4):261-8
   PubMed Web of Science ®Google Scholar
• Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16(2):121-9
   PubMed Web of Science ®Google Scholar
• Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987;144(12):1543-8
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989;46(1):36-44
   PubMed Web of Science ®Google Scholar
• Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990;147(9):1209-15
   PubMed Web of Science ®Google Scholar
• Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11(1):21-9
   PubMed Web of Science ®Google Scholar
• Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64(6):640-7
   PubMed Web of Science ®Google Scholar
• Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55(7):301-5
   PubMed Web of Science ®Google Scholar
• Milanfranchi A, Ravagli S, Lensi P, et al. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997;12(3):131-6
   PubMed Web of Science ®Google Scholar
• Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001;16(6):461-8
   PubMed Web of Science ®Google Scholar
• Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993;3(2):143-52
   PubMedGoogle Scholar
• Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51(7):559-67
   PubMed Web of Science ®Google Scholar
• Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990;47(10):926-32
   PubMedGoogle Scholar
• López-Ibor JJ Jr, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996;6(2):111-18
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Summergrad P, et al. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1990;147(7):923-8
   PubMed Web of Science ®Google Scholar
• Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26(3):279-84
   PubMedGoogle Scholar
• Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52(4):289-95
   PubMedGoogle Scholar
• Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 1999;19(2):172-6
   PubMed Web of Science ®Google Scholar
• Bisserbe J, Lane R, Flament M. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997;12(2):82-93
   PubMed Web of Science ®Google Scholar
• Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 2002;22(2):148-54
   PubMed Web of Science ®Google Scholar
• Kamijima K, Murasaki M, Asai M, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci 2004;58(4):427-33
   PubMed Web of Science ®Google Scholar
• Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996;169(4):468-74
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16(2):75-86
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007;23(4):701-11
   PubMed Web of Science ®Google Scholar
• Denys D, van der Wee N, van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23(6):568-75
   PubMed Web of Science ®Google Scholar
• Belotto-Silva C, Diniz JB, Malavazzi DM, et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord 2012;26(1):25-31
   PubMed Web of Science ®Google Scholar
• Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22(3):309-17
   PubMed Web of Science ®Google Scholar
• Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10(1):11-18
   PubMed Web of Science ®Google Scholar
• Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995;52(1):53-60
   PubMed Web of Science ®Google Scholar
• Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995;166(4):424-43
   PubMed Web of Science ®Google Scholar
• Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011;25(7):585-96
   PubMed Web of Science ®Google Scholar
• Ravindran LN, Jung SM, Ravindran AV. Intravenous anti-obsessive agents: a review. J Psychopharmacol 2010;24(3):287-96
   PubMed Web of Science ®Google Scholar
• Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67(1):15-22
   PubMed Web of Science ®Google Scholar
• Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol 2014;24(3):375-80
   PubMed Web of Science ®Google Scholar
• Luis Blay S, Black DW. A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry 2007;9(3):234-5
   PubMedGoogle Scholar
• Dell'osso B, Mundo E, Marazziti D, et al. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 2008;22(2):210-13
   PubMed Web of Science ®Google Scholar
• Yeh YW, Chen CH, Kuo SC, et al. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol 2009;32(3):174-6
   PubMed Web of Science ®Google Scholar
• Safer DL, Arnow KD. Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report. Innov Clin Neurosci 2012;9(3):13-16
   PubMedGoogle Scholar
• Arumugham SS, Reddy JY. Augmentation strategies in obsessive-compulsive disorder. Expert Rev Neurother 2013;13(2):187-202; quiz 03
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004;65(10):1394-9
   PubMed Web of Science ®Google Scholar
• Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005;66(4):515-20
   PubMed Web of Science ®Google Scholar
• Lennertz L, Wagner M, Grabe HJ, et al. 5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. Eur Neuropsychopharmacol 2014;24(1):86-94
   PubMed Web of Science ®Google Scholar
• Soltani F, Sayyah M, Feizy F, et al. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 2010;25(6):509-13
   PubMed Web of Science ®Google Scholar
• De Berardis D, Serroni N, Campanella D, et al. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J Clin Psychopharmacol 2012;32(2):289-90
   PubMed Web of Science ®Google Scholar
• da Rocha FF, Correa H. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD. Clin Neuropharmacol 2011;34(4):139-40
   PubMed Web of Science ®Google Scholar
• De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry 2012;2012:642752
   PubMedGoogle Scholar
• Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry 2011;10(1):5
   PubMed Web of Science ®Google Scholar
• Servier Laboratories. Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD). 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT01108393 NLM Identifier: NCT01108393 cited 15 February 2014
   Google Scholar
• Paterson JL, Reynolds AC, Ferguson SA, et al. Sleep and obsessive-compulsive disorder (OCD). Sleep Med Rev 2013;17(6):465-74
   PubMed Web of Science ®Google Scholar
• Moret C, Briley M. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 2000;404(1-2):1-12
   PubMed Web of Science ®Google Scholar
• Stahl SM, Lee-Zimmerman C, Cartwright S, et al. Serotonergic drugs for depression and beyond. Curr Drug Targets 2013;14(5):578-85
   PubMed Web of Science ®Google Scholar
• Yucel M, Harrison BJ, Wood SJ, et al. Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder. Arch Gen Psychiatry 2007;64(8):946-55
   PubMed Web of Science ®Google Scholar
• Wu K, Hanna GL, Rosenberg DR, et al. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012;100(4):726-35
   PubMed Web of Science ®Google Scholar
• Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990;147(6):798-800
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991;52(1):13-14
   PubMed Web of Science ®Google Scholar
• Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12(1):11-18
   PubMed Web of Science ®Google Scholar